Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2021 | MRD-negativity as a surrogate for PFS and OS

Philippe Moreau • 10 Sep 2021
IMW 2021
General Multiple Myeloma

Philippe Moreau, MD, Nantes University Hospital, Nantes, France, discusses the use of measurable residual disease (MRD) negativity as a surrogate for progression-free survival (PFS) and overall survival (OS) in both the frontline and relapsed/refractory setting. Prof. Moreau explores the key questions regarding the use of MRD, such as what the optimal techniques are to obtain the measure, such as through flow cytometry or next-generation sequencing (NGS), as well as what the optimal MRD threshold is. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.

More from Philippe Moreau

1:15
Overall survival data from the POLLUX trial: DRd versus Rd in patients with R/R multiple myeloma
Philippe Moreau • 15 Feb 2023
4:49
Factors to predict the outcomes of patients with R/R myeloma treated with CAR-T therapy
Philippe Moreau • 15 Feb 2023
3:02
Optimal treatment strategies for multiple myeloma
Philippe Moreau • 10 Sep 2021
1:59
Optimal treatment sequencing for relapsed/refractory myeloma
Philippe Moreau • 10 Sep 2021

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals